United States was Fulgent Genetics’s largest region in fiscal 2025, bringing in $296.55M of $322.67M (92%).
| Geography | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $603.15M | $268.98M | $259.13M | $296.55M | ||||||||
| Foreign | — | — | — | — | ||||||||
| China | $8.94M | $11.45M | $12.64M | $12.91M | ||||||||
| Peoples Republic Of China ("Prc") | — | — | — | — | ||||||||
| Other Countries | $6.88M | $8.79M | $11.70M | $13.21M | ||||||||
| Canada | — | — | — | — | ||||||||
| Total | $618.97M | $289.21M | $283.47M | $322.67M |
Fulgent Genetics brought in $322.67M from its three regions in fiscal 2025, the year ended December 31, 2025. That was up 13.8% from $283.47M in fiscal 2024. United States was the largest at $296.55M (91.9%), ahead of Other Countries at $13.21M (4.1%) and China at $12.91M (4.0%).
Compared with fiscal 2024, United States grew fastest, up 14.4% to $296.55M. Every region above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these regions fell from $618.97M to $322.67M, a compound annual decline of 19.5%. United States' share of the total fell from 97.4% to 91.9%.
Precision Diagnostics was Fulgent Genetics’s largest segment in fiscal 2025, bringing in $190.47M of $322.67M (59%).
| Segment | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Covid-19 | $437.51M | $27.15M | $2.31M | — | |
| Precision Diagnostics | $93.69M | $131.99M | $167.75M | $190.47M | |
| Anatomic Pathology | $74.80M | $104.66M | $97.08M | $106.44M | |
| Biopharma Services | $12.98M | $25.42M | $16.34M | $25.76M | |
| Total | $618.97M | $289.21M | $283.47M | $322.67M |
Fulgent Genetics brought in $322.67M from its three segments in fiscal 2025, the year ended December 31, 2025. Fulgent Genetics regrouped these segments after fiscal 2024, so the total does not compare directly with that year's $283.47M. Precision Diagnostics was the largest at $190.47M (59.0%), ahead of Anatomic Pathology at $106.44M (33.0%) and Biopharma Services at $25.76M (8.0%).
Compared with fiscal 2024, Biopharma Services grew fastest, up 57.7% to $25.76M. Every segment above 2% of revenue grew.
Fulgent Genetics stopped reporting Covid-19 as a separate segment after fiscal 2024, when it brought in $2.31M.
Clinical Institutional Contracts was Fulgent Genetics’s largest revenue line in fiscal 2025, bringing in $184.60M of $322.67M (57%).
| Accounting Standards Update | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Clinical Insurance Contracts | $377.87M | $151.95M | $123.92M | $130.25M | ||||
| Clinical Institutional Contracts | $239.96M | $134.19M | $154.73M | $184.60M | ||||
| Clinical Patient Contracts | $1.13M | $3.08M | $4.81M | $7.82M | ||||
| Total | $618.97M | $289.21M | $283.47M | $322.67M |
Fulgent Genetics brought in $322.67M from its three revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 13.8% from $283.47M in fiscal 2024. Clinical Institutional Contracts was the largest at $184.60M (57.2%), ahead of Clinical Insurance Contracts at $130.25M (40.4%) and Clinical Patient Contracts at $7.82M (2.4%).
Compared with fiscal 2024, Clinical Patient Contracts grew fastest, up 62.4% to $7.82M. Every revenue line above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these revenue lines fell from $618.97M to $322.67M, a compound annual decline of 19.5%. Clinical Institutional Contracts' share of the total rose from 38.8% to 57.2%.
Fulgent Genetics (FLGT) reports its revenue by geography, by segment and by accounting standards update. In fiscal 2025, United States was its largest region, bringing in $296.55M (91.9% of the total), followed by Other Countries at $13.21M (4.1%).
United States was Fulgent Genetics' largest region in fiscal 2025, bringing in $296.55M, or 91.9% of the $322.67M total across its three regions.
Precision Diagnostics was Fulgent Genetics' largest segment in fiscal 2025, bringing in $190.47M, or 59.0% of the $322.67M total across its three segments.
Clinical Institutional Contracts was Fulgent Genetics' largest revenue line in fiscal 2025, bringing in $184.60M, or 57.2% of the $322.67M total across its three revenue lines.
Among Fulgent Genetics' regions that make up at least 2% of revenue, United States grew fastest in fiscal 2025, up 14.4% from $259.13M to $296.55M.
Every figure comes from Fulgent Genetics' annual financial filings, as reported. Each line keeps the name Fulgent Genetics gives it, and years follow its fiscal calendar.
Fulgent Genetics' revenue by geography goes back to fiscal 2014, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.